Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
  • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
  • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/52—Cytokines; Lymphokines; Interferons
  • C07K14/54—Interleukins [IL]
  • C07K14/5428—IL-10
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide

Definitions

• interleukin-10 and more particularly to their use in preparing reagents useful for diagnosing or treating various receptor-related medical conditions.
• Cytokines play a variety of important roles in regulation of immune responses by controlling proliferation, differentiation, and the effector functions of immune cells.
• cytokines are typically mediated by specific receptor molecules found on target cells.
• One chain typically designated the ⁇ chain, can bind its cytokine ligand with low affinity. This interaction may or may not result in transduction to the cell of a signal.
• Another chain can bind its cytokine ligand with low affinity. This interaction may or may not result in transduction to the cell of a signal.
• the ⁇ chain when associated with the ⁇ chain, confers higher affinity binding of the heterodimeric receptor to the cytokine.
• the ⁇ chain by itself usually lacks significant ligand binding affinity.
• the dimeric form of receptor is capable of transducing a signal into the cell as a consequence of ligand. e.g., cytokine, binding.
• interleukin-10 interleukin-10
• IL-10 interleukin-10
• Fiorentino et al. J. Exptl. Med. 770:2081 (1989); and Mosmann et al., Immunol. Today 12.A49-A53 (1991 ).
• Both mouse and human counterparts have been isolated.
• Moore, et al. Science 248 :1230 (1990); and Vieira, et al. , Proc. Nat'l Acad. Sci. USA 55: 1 172 (1991 ).
• a human viral analog known as either vIL-10 or BCRF1 , has been described which shares many characteristic activities of the natural human form. See Hsu et al., Science 25(9:830 ( 1990).
• the present invention fills these needs by providing nucleic acids and protein sequences of components of a receptor for IL-10. Both a human IL-10 receptor component and a mouse counterpart are exemplified, though equivalent components from other
• the present invention provides recombinant or isolated nucleic acids comprising a sequence exhibiting homology to a sequence encoding a mammalian receptor for IL-10, a fragment thereof, or a unique portion thereof.
• the nucleic acids will comprise deoxyribonucleic acid, will be isolated, further comprise a regulatory sequence from the 5' or 3' sequence adjacent a gene encoding a receptor for IL-10, or are operably linked to a genetic control element.
• the receptors, fragments, or portions thereof have a biological activity, e.g., one characteristic of a receptor for IL-10, or are from a mammal, including a mouse or human.
• the nucleic acids are capable of hybridizing at high stringency to SEQ ID NO: 1 or 3, or are isolated using a probe which hybridizes at high stringency to a human receptor gene for IL-10.
• the invention also embraces nucleic acids capable of hybridizing to these sequences, e.g., which contain
• Alternative embodiments include recombinant nucleic acids which are operably linked to a genetic control element, e.g., a prokaryotic promoter element or a eukaryotic expression control element, including a viral promoter.
• a genetic control element e.g., a prokaryotic promoter element or a eukaryotic expression control element, including a viral promoter.
• Various embodiments include expression vectors for expressing DNA encoding a receptor for IL- 10, or fragments thereof, or vectors comprising these sequences and a selection marker.
• the invention also embraces host cells comprising an expression vector which is capable of expressing these receptors. Preferred host cell
• embodiments include prokaryotes, including gram negative and gram positive bacteria, including E. coli; lower eukaryotes, including yeasts; and higher eukaryotes, including animal cells such as mammalian and primate cells, including human.
• the receptor is selected from a human receptor for IL-10; or a mouse receptor for IL-10.
• Other embodiments include nucleic acids further encoding a second protein or polypeptide, e.g., where the second polypeptide is fused to the receptor or a fragment thereof.
• the invention further embraces subcellular structures, cells, or organisms comprising these nucleic acids.
• the present invention also embraces proteins or polypeptides encoded by these DNA sequences, preferably which are substantially free of protein or cellular contaminants, other than those derived from a recombinant host.
• the receptor proteins or polypeptides will often be from a mammal, including a mouse or human, and can have an amino acid sequence as found in SEQ ID NO: 2 or 4, or an allelic or species variant thereof, or a unique portion thereof.
• the receptor proteins or polypeptides can be attached to a solid support, be substantially pure, or be in a pharmaceutically acceptable form, with or without additional carriers or excipients.
• the invention also conceives of fusion proteins or polypeptides, including those further comprising a sequence from a second receptor protein. Other embodiments include subcellular structures, cells, or organisms comprising such receptor proteins or polypeptides.
• the invention also provides methods for producing receptor proteins or polypeptides comprising culturing a cell comprising a described nucleic acid in a nutrient medium; and expressing the receptor proteins or polypeptides in the cell.
• Various alternative embodiments further comprise a step of purifying the receptor proteins or polypeptides, where the receptor proteins or
• polypeptides are secreted into the medium and purified therefrom, and wherein the receptor is from a mammal, including a mouse or human.
• the invention also provides receptors made by these methods and exhibiting a post-translational modification pattern distinct from that in normal native receptor, e.g., glycosylation;
• the receptor can be made in a cell line expressing a receptor exhibiting a non-natural receptor glycosylation pattern.
• the invention also provides methods for diagnosing a medical condition characterized by inappropriate IL-10 response in a host comprising contacting a sample from the host with a specific binding reagent to (i) a nucleic acid encoding a receptor for IL-10 or fragment thereof; or to (ii) a receptor for IL-10 or fragment thereof, and measuring the level of binding of the reagent to the sample.
• the binding reagent is a nucleic acid probe for a gene encoding the receptor or fragment thereof, an antibody which recognizes a receptor for IL-10 or a fragment thereof; or a ligand, agonist, or antagonist for a receptor for IL-10.
• the receptor is from a mammal, including a mouse or human.
• the invention also provides methods of screening for a compound having binding affinity to a receptor for IL- 10, comprising producing an isolated or recombinant receptor by a method as described; and assaying for the binding of the compound to the receptor, thereby identifying compounds having defined binding affinity therefor.
• the compound is a ligand, agonist, or antagonist for these receptors.
• the present invention also provides proteins and polypeptides, e.g., free of proteins with which they are naturally associated and having an amino acid sequence homologous to a fragment of a receptor for IL-10.
• the receptor is from a mammal, including a mouse or human, and specific embodiments have sequence of SEQ ID NO: 2 or 4.
• the invention encompasses a recombinant or substantially pure polypeptides comprising a region exhibiting substantial identity to an amino acid sequence of a receptor for IL-10.
• Particular embodiments include polypeptides having a sequence selected from SEQ ID NO: 2 or 4, or polypeptides attached to a solid support.
• the present invention provides various antibodies having binding affinity to a recombinant receptor for IL- 10, or a fragment thereof.
• Preferred embodiments are raised against the receptor for IL-10, and can be either neutralizing or non-neutralizing antibodies, fused to a toxic moiety, or conjugated to a marker moiety, including a radionuclide.
• Binding fragments such as Fab and FV are also provided.
• the antibody or fragment binds to a receptor from a mammal, including a mouse or human.
• the invention provides methods of treating a host having a medical condition characterized by inappropriate IL-10 response or exhibiting abnormal expression of a receptor for IL-10, comprising administering to the host a therapeutically effective amount of a composition comprising (a) an antibody which binds to a receptor for IL-10 or fragment thereof; (b) a ligand, agonist, or antagonist for a receptor for IL- 10; or (c) a ligand binding receptor, or fragment thereof, for IL- 10.
• the antibody is a monoclonal antibody or an antigen-binding fragment thereof.
• the agonist or antagonist is selected by a method of contacting a target compound with (a) isolated or recombinant receptor for IL-10, or (b) ligand binding fragment of the receptor; and identifying the target compound with isolated or recombinant receptor for IL- 10, or ligand binding fragment of the receptor; and identifying the target compound based upon the effects of the contacting.
• the invention also provides methods of evaluating binding affinity of a test compound to a receptor for IL-10, the method comprising contacting (a) a sample containing the receptor, or a fragment thereof, with a labeled compound having known affinity for the receptor; and (b) the test compound; and measuring the level of bound labeled compound, the amount being inversely proportional to the amount of test compound which bound to the receptor.
• the receptor is from a mammal, including a mouse or human.
• An alternative embodiment is a method of modulating biological activity of a receptor for IL-10, comprising contacting the receptor with a composition selected from an antibody which binds to the receptor; a ligand, agonist, or antagonist for a receptor for IL-10; and a ligand binding fragment from a receptor for IL-10.
• the invention also provides useful reagents in kit form.
• kit form useful for (a) quantifying a receptor for IL-10; or (b) for determining the binding affinity of a test sample to a receptor for IL-10; the kit comprising a labeled compound having binding affinity for the receptor, and a means for measuring bound labeled compound.
• the invention also provides a kit for assaying, in a sample, antibody against a receptor for IL-10, comprising the receptor and an
• the receptor is attached to a solid support.
• Kits containing DNA probes for use in assaying, e.g., human IL-10 mRNA, are also provided.
• the invention also provides compounds known to modulate activity of a receptor for IL-10, selected by a method of: contacting the compound with isolated or recombinant receptor, or a fragment thereof, for IL-10; and evaluating the effect on biological activity by the contacting.
• the invention also provides methods of modulating a biological effect of IL-10. comprising a step of interfering with biological mechanisms, e.g., signal transduction, of a class 2 cytokine receptor, e.g., an interferon receptor. It also provides methods of modulating a biological effect of a class 2 receptor, e.g., an interferon, comprising a step of interfering with biological mechanisms of an IL-10 receptor.
• a biological effect of IL-10 comprising a step of interfering with biological mechanisms, e.g., signal transduction, of a class 2 cytokine receptor, e.g., an interferon receptor.
• the present invention provides amino acid and DNA sequences for mammalian IL- 10 receptor subunits, exemplified by human and mouse IL- 10 receptor subunits. These sequences were obtained by screening pools of cells containing cDNA expression library products for specific binding to IL- 10. Receptor-ligand complexes thus produced were chemically crosslinked, and methods were applied to isolate nucleic acids encoding the binding proteins.
• nucleic acids and isolated or purified nucleic acids are substantially homologous to a sequence encoding an IL-10 receptor subunit, or a fragment thereof.
• Nucleic acids encoding fusion polypeptides are also contemplated, as are vectors,
• IL-10 receptor subunits or fragments thereof derived from such nucleic acids are also a part of this invention.
• the present invention also provides antibodies specific for epitopes on the receptor subunits. These include antibodies which bind specifically to epitopes that are common to receptors for IL-10 from different species, or epitopes that are unique to receptors from one species.
• Kits comprising these materials are included herein.
• the various nucleic acids, polypeptides and antibodies in the kits can be used for various diagnostic or therapeutic purposes.
• the various materials can be used in methods for treating mammals, particularly those suffering from undesired receptor function, e.g., autoimmune diseases, inappropriate immune responses of the T helper 2 class, inappropriate function of class II MHC, suppressed monocyte or macrophage-related immune functions, septic or toxic shock responses, and intracellular pathogen-mediated diseases.
• autoimmune diseases e.g., autoimmune diseases, inappropriate immune responses of the T helper 2 class, inappropriate function of class II MHC, suppressed monocyte or macrophage-related immune functions, septic or toxic shock responses, and intracellular pathogen-mediated diseases.
• These methods comprise administering effective amounts of the materials, or contacting biological samples with them.
• the materials of the present invention can also be used to select and screen for agonists and antagonists specific for the receptors.
• soluble forms of the receptor subunits lacking the cytoplasmic and/or transmembrane domain can be prepared and immobilized by standard methods on solid supports, and used to specifically bind ligands.
• Ligands can thus be identified which specifically bind to the extracellular binding sites, or to the intracellular domain of the IL-10 receptor.
• ligands affecting multiple receptor types of the class to which IL-10 receptors belong i.e., Class 2 receptor types. Class 2 receptors are described more fully below.
• Antibodies can also be prepared which specifically bind to the ligand recognition sites, or to other regions of the receptors.
• the receptor subunits or fragments thereof, or synthetic polypeptides having sequences corresponding to subsequences of the subunits, can be used as antigens in conventional methods to produce such antibodies .
• Such other species may include other warm-blooded species such as birds or primates.
• Standard methods are used herein, e.g., as described in
• cDNA libraries were constructed using messenger RNA (mRNA) isolated from cells that were responsive to IL-10.
• mRNA messenger RNA isolated from cells that were responsive to IL-10.
• a B cell line designated BJAB was used to make a cDNA library of human origin, and mast and macrophage cell lines
• the IL-10 used as a ligand was modified by addition of an N-terminal extension which provided a means to detect a ligand- receptor crosslinked complex.
• the extension used was a FLAG peptide which was specifically recognized by an antibody, although other extensions could have been used instead. See Hopp et al. , BiolTechnology 6 : 1204 (1988). It was not known whether the extension would interfere with ligand-receptor interaction, or whether any IL- 10 binding protein interactions observed would be physiologically relevant.
• the present invention encompasses the unglycosylated receptor subunits actually sequenced, allelic variants of the protein and various metabolic variants, e.g., post-translational modifications, produced by different cell types, including natural cells and host cells used in recombinant expression systems.
• various metabolic variants e.g., post-translational modifications
• Various glycosylation variants and post-translational modification variants can be
• IL-10 receptor subunit IL- 10R nucleotide sequence and the predicted amino acid sequence are defined by SEQ ID NOs: 1 and 2, respectively.
• the mouse nucleotide sequence and the amino acid sequence predicted therefrom are defined by SEQ ID NOs: 3 and 4, respectively.
• the initiation codon in SEQ ID NO: 3 begins at base 61 .
• the human sequence was derived from a clone designated SW8.1 , which was deposited in a plasmid with the American Type Culture Collection, Rockville, MD (ATCC) on December 4, 1992, and assigned accession number ATCC 69146.
• a hydrophobic membrane spanning segment appears to correspond to amino acids 217-243 of the human receptor component.
• a soluble binding fragment would correspond to one extending from about residues 1 -216, or shorter.
• the mouse sequence was derived from a clone designated pMR29, which was deposited in a plasmid with the ATCC on
• IL-10 receptor subunit encompasses a protein or peptide comprising an amino acid sequence defined by SEQ ID NO: 2 or 4, or encoded by a nucleic acid sequence defined by SEQ ID NO: 1 or 3. This term also encompasses fragments of such proteins or polypeptides which specifically bind IL-10. Such fragments can be made by proteolytic cleavage, chemical synthesis or recombinant methods.
• IL- 10 receptor subunits of this invention bind to IL-10 such as human or mouse IL-10 with high affinity, e.g., at least about 10 nM, usually better than about 3 nM, preferably better than about 1 nM, and more preferably at better than about 0.5 nM. It is expected that the binding affinity of a multiprotein complex to the ligand will be higher when additional protein components associate with the component disclosed herein, e.g., an ⁇ -like chain.
• the present invention also encompasses proteins or peptides having substantial amino acid sequence homoiogy with the amino acid sequences defined herein but excludes any protein or peptide exhibiting substantially the same or lesser amino acid sequence homoiogy than do known G-CSF, GM-CSF, EPO, TNF. IFN- ⁇ , IL-2, IL-3,
• peptides do not bind IL-10 but may instead bind as yet uncharacterized intracellular molecules involved in signal transduction or other interactions with the receptors. These peptides may have amino acid sequences corresponding to sequences of the receptor intracellular or transmembrane domains. Other peptides which may not have known binding capabilities are also provided. Because they have amino acid sequences
• these peptides are useful, e.g., as antigens for the production of antibodies.
• Amino acid sequence homoiogy, or sequence identity is determined by optimizing residue matches, if necessary, by
• Conservative substitutions typically include substitutions within the following groups: [glycine, alanine]; [valine, isoleucine, leucine] ; [ aspartic acid, glutamic acid] ; [asparagine, glutamine] ; [ serine, threonine] ; [lysine, arginine]; and
• homologous amino acid sequences are intended to include natural allelic and interspecies variations in each respective receptor sequence.
• Typical homologous proteins or peptides will have from
• homoiogy measures will be at least about 50%, generally at least 56%, more generally at least 62%, often at least 67%, more often at least 72%, typically at least 77%, more typically at least 82%, usually at least 86%, more usually at least 90%, preferably at least 93%, and more preferably at least 96%, and in particularly preferred embodiments, at least 98% or more.
• Some homologous proteins or peptides, such as the various receptor subtypes, will share various biological activities with the components of a receptor for IL- 10, e.g., the embodiments used to illustrate this invention .
• biological activity is defined as including, without limitation, ligand (e.g., IL-10-like protein) binding, cross-reactivity with antibodies raised against each respective receptor component, and ligand dependent signal transduction.
• ligand-related activity refers either to ligand binding itself, or to biological activities which are mediated by ligand binding, including, e.g., second messenger modulation, Ca ++ sequestration.
• ligand refers to molecules, usually members of the family of cytokine-like peptides, that bind to the receptor via the segments involved in peptide ligand binding.
• a ligand is a molecule which serves either as a natural ligand to which the receptor, or an analog thereof, binds, or a molecule which is a functional analog of a natural ligand.
• the functional analog may be a ligand with structural modifications, or may be a wholly unrelated molecule which has a molecular shape which interacts with the appropriate ligand binding determinants.
• the ligands may serve as agonists or antagonists, see, e.g., Goodman et al., (eds), Goodman & Gilman's: The Pharmacological Bases of Therapeutics (8th ed), 1990, Pergamon Press.
• Particularly useful soluble fragments of the receptor subunits bind the IL-10 ligand. Because the complete receptor appears to contain extracellular domains with which the ligand should bind, a protein comprising the extracellular segments amino proximal to the transmembrane helix segment running from residues 217-243 would exhibit such binding activity. Fusions of the extracellular domain with other proteins, and shorter segments can be easily tested for ligand binding activity. Fragments consisting of the intracellular domain may also be useful.
• the human and mouse IL- 10 receptor subunits exhibit 70-75% homoiogy at the DNA and protein sequence levels.
• the IL- 10 receptor subunits are members of the class 2 group of the cytokine receptor superfamily.
• the characteristic motifs of the class 1 receptors include an amino-terminal set of four conserved cystines and one tryptophan residue, and a carboxy-terminal (membrane-proximal) collection of spaced aromatic residues.
• the motifs characteristic of the class 2 receptors are a conserved tryptophan and the second cysteine pair in the amino-terminal half, a WSxWS box analog in the carboxy- terminal half, and a second conserved cysteine pair.
• the other members of class 2 are the receptors for interferon- ⁇ (IFN- ⁇ ), interferon- ⁇ (IFN- ⁇ ), tissue factor, and for a second soluble viral IFN receptor homolog.
• the IL- 10 receptor components include an amino-terminal set of four conserved cystines and one tryptophan residue, and a carboxy-terminal (membrane-proximal) collection of spaced aromatic residues.
• the motifs characteristic of the class 2 receptors are a conserved tryptophan and the second cyste
• the antagonistic effect of IL- 10 on macrophage activation by IFN- ⁇ may directly intervene in the signal cascade of IFN response. This may be effected by interaction of a component in the IFN signal pathway with a component in the IL-10 pathway.
• Sharing of components in the two pathways is a real possibility, including direct structural overlap of one or more components in active receptor complexes, e.g., shared ⁇ -like subunits.
• the structural similarities of the IFN and IL-10 receptor components will predict that regions of receptor structure critical in one pathway and conserved in the other will have like importance. This predictability extends to both ligand molecular surface shapes and to intracellular features likely to interact with downstream signal pathway components. This suggests methods of modulating a biological effect of IL-10, comprising a step of
• interferon receptor including, e.g., agonists or antagonists of an IFN, or homologous IL-10 receptor variants to IFN receptor mutants.
• Neutralizing antibodies to conserved regions would thus be expected to have similar effects on other receptors in the family.
• This invention contemplates use of the isolated nucleic acids, e.g., DNA, or fragments which encode the IL- 10 receptor subunits. Furthermore, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which are
• the isolated DNA can have the respective regulatory sequences in the 5' and 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others known in the art.
• Such nucleic acids are generally useful as probes, e.g., for genes of mRNA encoding IL- 10 receptors or fragments thereof.
• nucleic acid as defined herein is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and flanking genomic sequences from the originating species.
• the term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogues or analogues biologically
• a substantially pure molecule includes isolated forms of the molecule.
• An isolated nucleic acid will generally be a homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.
• a "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence. Alternatively, it can be a nucleic acid made by generating a sequence comprising fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants.
• products made by transforming cells with any unnaturally occurring vector are encompassed, as are nucleic acids comprising sequence derived using any synthetic
• oligonucleotide process This is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly
• a nucleic acid "fragment” is defined herein to be a contiguous segment of at least about 17 nucleotides, generally at least 21 nucleotides, more generally at least 25 nucleotides, ordinarily at least 30 nucleotides, more ordinarily at least 35 nucleotides, often at least 42 nucleotides, more often at least 49 nucleotides, typically at least 58 nucleotides, more typically at least 75 nucleotides, usually at least 100 nucleotides, more usually at least 200 nucleotides, preferably at least 300 nucleotides, more preferably at least 500 nucleotides, and in particularly preferred embodiments will be at least 800 or more nucleotides.
• fragment thereof can be used to identify genes, mRNA and cDNA species which code for related or homologous receptors, as well as nucleic acids which code for species variants of these receptor components.
• Preferred probes for such use encode regions of the receptors which are conserved between different species variants. conserveed regions can be identified by sequence comparisons.
• This invention further covers recombinant DNA molecules and fragments having a DNA sequence identical to or highly homologous to the isolated DNAs set forth herein.
• the sequences will often be operably linked to DNA segments which control transcription, translation, and DNA replication.
• Genomic sequences containing introns are also made available, along with methodologies to isolate them.
• homoiogy in nucleic acids when compared, exhibit significant similarity.
• the standards for homoiogy in nucleic acids are either measures for homology generally used in the art by sequence comparison or based upon hybridization conditions. The hybridization conditions are described in greater detail below, but are further limited by the homoiogy to other known receptors for cytokines, e.g., the above described receptor components. Homology measures will be limited, in addition to any stated parameters, to exceed any such similarity to these receptors, e.g., GM-CSF, IL-3, IL-4, and IL-5 receptor components.
• Substantial nucleic acid sequence homology means either that the segments or their complementary strands are identical when optimally aligned, with appropriate nucleotide insertions or
• deletions in at least about 50% of the nucleotides, generally at least 56%, more generally at least 59%, ordinarily at least 62%, more ordinarily at least 65%, often at least 68%, more often at least 71 %, typically at least 74%, more typically at least 77%, usually at least 80%, more usually at least about 85%, preferably at least about 90%, more preferably at least about 95 to 98% or more, and in particular embodiments, as high as about 99% or more of the nucleotides.
• Substantial homoiogy also exists when the segments will hybridize under selective (stringent) hybridization conditions to a strand or its complement, typically using a sequence defined herein.
• the length of homoiogy comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 40 nucleotides,
• nucleotides preferably at least about 50 nucleotides, and more preferably at least about 75 to 100 or more nucleotides.
• hybridization context will be stringent combined conditions of salt, temperature, organic solvents, and other parameters typically controlled in hybridization reactions. Stringent temperature
• Stringent salt conditions will ordinarily be less than about 1000 mM, often less than about 700 mM, usually less than about 500 mM, more usually less than about 400 mM, typically less than about 300 mM,
• Nucleic acids isolated and characterized as described herein can be used to make variants and mutants. They also can be used to make vector constructs useful, e.g., for making transgenic cells, including homologous recombination, e.g., gene "knock-out” animals, and for gene therapy. See, e.g., Goodnow, "Transgenic Animals” in Roitt (ed.), Encyclopedia of Immunology, 1992, Academic Press, San Diego, pp. 1502-1504; Travis, Science 256:1392 (1992); Kuhn, et al., Science 254:101 (1991 ); Capecchi, Science 244: 1288 (1989);
• the isolated receptor DNAs can be readily modified by
• nucleotide substitutions deletions, insertions and inversions.
• IL- 10 binding capability is maintained in expression products.
• Mutant receptors thus produced can readily be tested for specific binding to IL-10 as disclosed herein.
• modified sequences can be prepared using well known methods such as site-specific mutagenesis. Modified sequences can also be prepared, e.g., using modified primers, the sequences described herein, and the polymerase chain reaction (PCR).
• the present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments from the receptor subunits.
• a heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner.
• the fusion product of an immunoglobulin with a receptor polypeptide is a continuous protein molecule having sequences fused in a typical peptide linkage, e.g.. typically made as a single translation product and exhibiting properties derived from each source peptide.
• a similar concept applies to heterologous nucleic acid sequences.
• new constructs may be made from combining similar functional domains from other proteins.
• ligand-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g.,
• the present invention provides means to produce fusion proteins.
• Various receptor variants may have slightly different functions or biological activities, even though they share significant structural similarities. Dissection of structural elements which effect the various physiological functions or biological activities provided by the receptors is possible using standard techniques of modern molecular biology, particularly in comparing variants within the related family of cytokine receptors. See, e.g., the homolog-scanning mutagenesis technique described in Cunningham et al. , supra, and approaches used in O'Dowd et al., supra, and Lechleiter et al., EMBO J. 9 :4381 ( 1990).
• Ligand binding segments can be substituted between receptors to determine what structural features are important in both ligand binding affinity and specificity.
• the segments of receptor accessible to an extracellular ligand would be primary targets of such analysis.
• An array of different receptor variants, e.g., allelic, will be used to screen for ligands exhibiting combined properties of interaction with them.
• Intracellular functions would probably involve segments of the receptor which are normally accessible to the cytosol. However, receptor internalization may occur under certain circumstances, and interaction between intracellular components and the designated "extracellular" segments may occur. These intracellular functions usually involve signal transduction from ligand binding.
• the specific segments of interaction of receptor with other proteins may be identified by mutagenesis or direct biochemical means, e.g., cross- linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Identification of the similarities and differences between receptor variants exhibiting distinct functions will lead to new diagnostic and therapeutic reagents or treatments.
• fragments thereof are available in the pMR29 and pSW8.1 clones, or can be obtained by chemical synthesis or by screening cDNA or genomic libraries prepared from cell lines or tissue samples.
• nucleic acids can be expressed in a wide variety of host cells for the synthesis of a full-length receptor subunit or fragments of a receptor which can in turn, for example, be used to generate polyclonal or monoclonal antibodies; for binding studies; for
• Each receptor or its fragments can be expressed in host cells that are transformed or transfected with appropriate expression vectors. These molecules can be substantially free of protein or cellular contaminants, other than those derived from the recombinant host, and therefore are particularly useful in pharmaceutical compositions when combined with a
• the receptor or portions thereof, may be expressed as fusions with other proteins.
• Expression vectors are typically self-replicating DNA or RNA constructs containing, e.g., the desired receptor gene or its fragments, usually operably linked to suitable genetic control elements that are recognized in a suitable host cell. These control elements are capable of effecting expression within a suitable host. The specific type of control elements necessary to effect expression wi ll depend upon the eventual host cell used.
• the genetic control elements can include a prokaryotic promoter system or a eukaryotic promoter expression control system, and typically include a transcriptional promoter, an optional operator to control the onset of transcription, transcription enhancers to elevate the level of mRNA expression, a sequence that encodes a suitable ribosome binding site, and sequences that terminate transcription and translation. Expression vectors also usually contain an origin of replication that allows the vector to replicate independently of the host cell.
• the vectors of this invention contain DNA which encodes a receptor for an IL-10-like peptide, or a fragment thereof encoding a biologically active receptor polypeptide.
• the DNA can be under the control of a viral promoter and can encode a selection marker.
• This invention further contemplates use of such expression vectors which are capable of expressing eukaryotic cDNA coding for a receptor in a prokaryotic or eukaryotic host, where the vector is compatible with the host and where the eukaryotic cDNA coding for the receptor is inserted into the vector such that growth of the host containing the vector expresses the cDNA in question.
• expression vectors are designed for stable replication in their host cells or for
• amplification to greatly increase the total number of copies of the desirable gene per cell. It is not always necessary to require that an expression vector replicate in a host cell, e.g., it is possible to effect transient expression of the IL-10 receptor or its fragments in various hosts using vectors that do not contain a replication origin that is recognized by the host cell. It is also possible to use vectors that cause integration of IL- 10 receptor or its fragments into the host DNA by recombination.
• Vectors as used herein, comprise plasmids, viruses,
• Expression vectors are specialized vectors which contain genetic control elements that effect expression of operably linked genes. Plasmids are the most commonly used form of vector, but other forms of vectors which serve an equivalent function and which are, or become, known in the art are suitable for use herein. See, e.g.,
• Transformed cells are cells, preferably mammalian, that have been transformed or transfected with receptor vectors constructed using recombinant DNA techniques.
• Transformed host cells usually express the receptor or its fragments, but for purposes of cloning, amplifying, and manipulating its DNA, do not need to express the receptor.
• This invention further contemplates culturing transformed cells in a nutrient medium, thus permitting the receptor or
• the receptor proteins can be recovered from the cells or from the culture medi um .
• DNA sequences are operably linked when they are functionally related to each other.
• DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or
• a promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation.
• operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression.
• Suitable host cells include prokaryotes, lower eukaryotes, and higher eukaryotes.
• Prokaryotes include both gram negative and gram positive organisms, e.g., E. coli and B. subtilis. Lower
• eukaryotes include yeasts, e.g., S. cerevisiae and Pichia, and species of the genus D ictyostelium .
• Higher eukaryotes include established tissue culture cell lines from animal cells, both of non-mammalian origin, e.g., insect cells, and birds, and of mammalian origin, e.g., human, primates, and rodents.
• Prokaryotic host-vector systems include a wide variety of vectors for many different species. As used herein. E. coli and its vectors will be used generically to include equivalent vectors used in other prokaryotes.
• a representative vector for amplifying DNA is pBR322 or many of its derivatives.
• Vectors that can be used to express the receptor or its fragments include, but are not limited to. such vectors as those containing the lac promoter (pUC-series); trp promoter (pBR322-trp); Ipp promoter (the pIN-series); lambda-pP or pR promoters (pOTS); or hybrid promoters such as ptac (pDR540). See Brosius et al., "Expression Vectors Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", in Vectors: A Survey of Molecular
• Lower eukaryotes e.g., yeasts and D ictyostelium, may be transformed with IL- 10 receptor sequence containing vectors.
• the most common lower eukaryotic host is the baker's yeast, Saccharomyces cerevisiae. It will be used to generically represent lower eukaryotes although a number of other strains and species are also available.
• Yeast vectors typically consist of a replication origin (unless of the integrating type), a selection gene, a promoter, DNA encoding the receptor or its fragments, and sequences for translation termination, polyadenylation, and
• Suitable expression vectors for yeast include such constitutive promoters as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters or such
• Suitable vectors include derivatives of the following types: self-replicating low copy number (such as the YRp- series), self-replicating high copy number (such as the YEp-series); integrating types (such as the YIp-series), or mini-chromosomes (such as the YCp-series).
• eukaryotic cells grown in tissue culture are often the preferred host cells for expression of the functionally active IL-10 receptor protein.
• any higher eukaryotic tissue culture cell line is workable, e.g., insect baculovirus expression systems, whether from an invertebrate or vertebrate source.
• mammalian cells are often preferred. Transformation or transfection and propagation of such cells has become a routine procedure.
• Examples of useful cell lines include HeLa cells, Chinese hamster ovary (CHO) cell lines, baby rat kidney (BRK) cell lines, insect cell lines, bird cell lines, and monkey (COS) cell lines.
• Expression vectors for such cell lines usually include an origin of replication, a promoter, a translation initiation site, RNA splice sites (if genomic DNA is used), a polyadenylation site, and a
• Suitable expression vectors may be plasmids, viruses, or retroviruses carrying promoters derived, e.g., from such sources as from adenovirus. SV40,
• parvoviruses parvoviruses, vaccinia virus, or cytomegalovirus.
• suitable expression vectors include pCDNA 1 (Invitrogen, San Diego, CA); pCD [Okayama et al., Mol. Cell Biol. 5: 1 136 (1985)] ; pMClneo Poly-A [Thomas et al., Cell 51 :503 (1987)]; and a
• baculovirus vector such as pAC 373 or pAC 610 [O'Reilly et al. , Baculovirus Expression Vectors: A Laboratory Manual, 1992,
• a receptor polypeptide in a system which provides a specific or defined glycosylation pattern.
• the usual pattern will be that provided naturally by the expression system.
• the pattern will be modifiable by exposing the polypeptide, e.g., an unglycosylated form, to appropriate glycosylating proteins introduced into a heterologous expression system.
• the receptor gene may be co-transformed with one or more genes encoding mammalian or other glycosylating enzymes. Using this approach, certain mammalian glycosylation patterns will be achievable in prokaryote or other cells.
• the nucleic acids of the invention will provide useful source materials possessing high levels of receptor proteins. Cells
• proteins expressing these proteins can be sources for protein purification, of the natural receptor forms, or variants thereof.
• purification segments can be fused to appropriate portions of the receptor to assist in isolation and production.
• the FLAG sequence, or a functional equivalent can be fused to the protein via a protease-removable sequence, allowing the FLAG sequence to be recognized by an affinity reagent, and the purified protein subjected to protease digestion to remove the extension.
• Many other equivalent segments exist, e.g., poly-histidine segments possessing affinity for heavy metal column reagents.
• appropriate host cells may be used to express the receptor proteins at high levels and under physiological conditions which may allow for desirable post-translational processing, e.g., glycosylation variants.
• Standard protein purification techniques are applied to purify the IL-10 receptor components to near homogeneity. These will include such methods as ammonium sulfate precipitation, column
• This invention also provides salts and labeled derivatives of the IL- 10 receptor subunits.
• Such derivatives may involve covalent or aggregative association with chemical moieties.
• These derivatives generally fall into three classes: ( 1 ) salts, (2) side chain and terminal residue covalent modifications, and (3) adsorption complexes, for example with cell membranes.
• derivatives are useful as immunogens. as reagents in immunoassays, or in purification methods such as for affinity purification of IL-10 or other binding ligands.
• the 1L- 10 receptor or a soluble form thereof can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated Sepharose, by methods which are well known in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of anti-IL- 10 receptor antibodies or IL- 10.
• the IL-10 receptor can also be labeled , with a detectable group, for example radioiodinated by the chloramine T procedure, covalently bound to rare earth chelates, or conjugated to another fluorescent moiety for use in diagnostic assays.
• the solubilized IL- 10 receptor of this invention can be used as an immunogen for the production of antisera or antibodies specific for the receptor or fragments thereof.
• the purified receptor can be used to screen monoclonal antibodies or antigen-binding fragments prepared by immunization with various forms of impure
• antibodies also encompasses antigen binding fragments of natural antibodies.
• the purified receptor can also be used as a reagent to detect any antibodies generated in response to the presence of elevated levels of IL- 10 receptor or cell fragments containing the IL-10 receptor.
• IL-10 receptor fragments may also serve as immunogens to produce the antibodies of the present invention, as described immediately below.
• this invention contemplates antibodies having binding affinity to or being raised against the amino acid sequences defined herein, or fragments thereof.
• this invention contemplates antibodies having binding affinity to or being raised against specific fragments which are predicted to lie outside of the lipid bilayer. These fragments should become readily apparent upon completion of the sequence of the human or mouse receptors.
• this invention covers fragments of the IL- 10 receptor which are predicted to reside on the extracellular side of the membrane. Analysis of protein structure to identify membrane associated regions is described, e.g., in von Heijne, J. Mol. Biol. 225:487 (1992); and Fasman et al., Trends in
• Antibodies can be raised to the various species variants of the receptor subunits and fragments thereof, both in their naturally occurring forms and in their recombinant forms. Additionally, antibodies can be raised to IL- 10 receptors in either their active forms or in their inactive forms, the difference bein g that antibodies to the active receptor are more likely to recognize epitopes which are only present in the active receptor. Anti-idiotypic antibodies can also be prepared by standard methods.
• Antibodies including binding fragments and single chain versions, against predetermined fragments of the IL- 10 receptor can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective IL-10 receptors, or screened for agonistic or antagonistic IL- 10 receptor activity.
• These monoclonal antibodies will normally bind with at least a Kd of about 1 mM, more normally at least 300 ⁇ M, generally at least 100 ⁇ M, more generally at least 30 ⁇ M, ordinarily at least 10 ⁇ M , more ordinarily at least 3 ⁇ M, often at least 1 ⁇ M, more often at least 300 nM, typically at least 100 nM, more typically at least 30 nM, usually at least 10 nM, more usually at least 3 nM, preferably at least 1 nM, more preferably at least 300 pM, and in especially preferred embodiments at least 100 to 10 pM or better.
• the antibodies, including antigen binding fragments, of this invention can have significant diagnostic or therapeutic value. They can be potent antagonists that bind to the IL-10 receptor and inhibit ligand binding to the receptor or inhibit the ability of an IL-10-like peptide to elicit a biological response. They also can be useful as non-neutralizing antibodies and can be coupled to toxins or
• these antibodies can be conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker.
• the antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can bind to the IL- 10 receptor without inhibiting ligand binding. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying IL-10 or IL- 10 receptors. Receptor fragments may be joined to other materials,
• polypeptides as fused or covalently joined polypeptides to be used as immunogens.
• the IL-10 receptor and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc.
• immunogens such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc.
• monoclonal antibodies from various mammalian hosts, such as mice, rodents, cows, sheep, goats, donkeys, primates, humans, etc.
• Descriptions of techniques used for preparing such monoclonal antibodies may be found in, e.g., Stites et al. (eds), Basic and Clinical Immunology, 4th ed., Lange Medical Publications. Los Altos, CA; Harlow and Lane, Antibodies: A Laboratory Manual, 1988, CSH Press; Goding,
• this method involves injecting an animal with an immunogen.
• the animal is then sacrificed and cells taken from its spleen, which are then fused with myeloma cells.
• the result is a hybrid cell or "hybridoma" that is capable of reproducing in vitro.
• the population of hybridomas is then screened to isolate individual clones, each of which secretes a single antibody species to the immunogen.
• the individual antibody species obtained are the products of immortalized and cloned single B cells from the immune animal generated in response to a specific site recognized on the immunogenic substance.
• lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors.
• Huse et al. "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246: 1215 ( 1989); and Ward et al. , Nature 341 :544 ( 1989).
• the polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or
• the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal.
• labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors,
• Patents disclosing the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275, 149; and 4,366,241 . Also, recombinant
• immunoglobulins may be produced, see Cabilly, U.S. Patent No.
• the antibodies of this invention can be used for affinity chromatography in isolating the receptor.
• Columns can be prepared where the antibodies are linked to a solid support, e.g., particles, such as agarose, Sephadex, or the like, where a cell lysate may be passed through the column, the column washed, followed by increasing concentrations of a mild denaturant. whereby the purified receptor protein will be released.
• the antibodies may also be used to screen expression
• antibodies used in such a procedure will be labeled with a moiety, allowing easy detection of presence of antigen by antibody binding.
• the anti-idiotypic antibodies are useful for detecting or diagnosing various immunological conditions related to expression of the respective receptors.
• Soluble receptor fragments can also be used as carriers for IL-10, e.g., to protect the cytokine from various degradative or other activities.
• the complex may be useful in certain situations as a slow release composition, allowing slow functional release of the cytokine or antagonist.
• soluble forms of the receptor e.g., a fragment containing the cytokine binding portions without membrane associated segments, will be useful diagnostic or therapeutic compositions.
• diagnostic reagent such fragment may be used as a substitute for antibodies against IL-10, but will likely be equivalent to a neutralizing antibody.
• the isolated component described herein is analogous to ⁇ subunits of other cytokine receptors.
• a unique ⁇ component for the IL- 10 receptor may exist, and could, in association with these components, modulate the activity from IL-10 binding.
• This will provide a convenient means to isolate this putative ⁇ subunit. See, e.g., Hayashida et al., Proc. Nat'l. Acad. Sci. USA 87:9655 (1990).
• species or tissue specific accessory molecules e.g., proteins, may provide a context for modification of the receptor protein properties or activities.
• Both the natural ly occurring and the recombinant form of the IL- 10 receptor subunits of this invention are useful in kits and assay methods which are capable of screening compounds for binding activity to the receptors.
• Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds per year. See, e.g.. Fodor et al., Science 251 :161 ( 1991 ), which describes methods for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. Phage or other libraries of various random polypeptide sequences would also be useful .
• the development of suitable assays can be greatly facilitated by the availability of large amounts of purified, soluble receptor such as is provided by this invention.
• antagonists can normally be found once the receptor has been characterized. Testing of potential receptor antagonists is now possible upon the development of highly
• This invention is particularly useful for screening compounds by using the recombinant receptors in any of a variety of drug screening techniques.
• the advantages of using a recombinant receptor in screening for receptor reactive drugs include:
• One method of drug screening utilizes eukaryotic or
• prokaryotic host cells which are stably transformed with
• Cells may be isolated which express a receptor in isolation from any others. Such cells, either in viable or fixed form, can be used for standard receptor/ligand binding assays. See Parce et al., Science 246:243 (1989); and Owicki et al., Proc. Nat'l. Acad. Sci. USA 57:4007 (1990).
• a source of IL-10 receptor a source of IL-10 receptor
• a labeled ligand having known binding affinity to the receptor such as 1 25 I-IL- 10
• a test compound whose binding affinity to the IL-10 receptor is being measured.
• the bound ligand and free ligand are then separated to assess the degree of ligand binding.
• the amount of test compound bound is inversely proportional to the amount of labeled ligand binding measured. Any one of numerous techniques can be used to separate bound from free ligand to assess the degree of ligand binding. This separation step could typically involve a procedure such as adhesion to filters followed by washing, adhesion to plastic followed by washing, or centrifugation of the cell
• Viable cells can also be used to screen for the effects of drugs on IL-10 receptor mediated functions, e.g., second messenger levels, i.e., Ca ++ ; cell proliferation; inositol phosphate pool changes; levels of phosphorylation; nitrous oxide levels; and others.
• second messenger levels i.e., Ca ++
• cell proliferation i.e., cell proliferation
• inositol phosphate pool changes levels of phosphorylation
• nitrous oxide levels nitrous oxide levels
• Some detection methods allow for elimination of a separation step, e.g.. a proximity sensitive detection system.
• Calcium sensitive dyes will be useful for detecting Ca ++ levels, with a fluorimeter or a fluorescence cell sorting apparatus. See Lowenstein et al., Cell 70:105 ( 1992).
• Another method utilizes membranes from transformed eukaryotic or prokaryotic host cells as the source of the IL-10 receptor. These cells are stably transformed with DNA vectors directing the expression of the IL- 10 receptor. Essentially, the membranes would be prepared from the cells and used in an appropriate receptor/ligand binding assay, e.g., the competitive assay set forth above.
• Still another approach is to use solubilized, unpurified or solubilized, purified receptors from transformed eukaryotic or prokaryotic host cells. This allows for a "molecular" binding assay with the advantages of increased specificity, the ability to automate, and high drug test throughput.
• Another technique for drug screening involves an approach which provides high throughput screening for compounds having suitable binding affinity to the IL- 10 receptor and is described in detail in Geysen, European Patent Application 84/03564.
• a solid substrate e.g., plastic pins or some other appropriate surface.
• all the pins are reacted with solubilized, unpurified or solubilized, purified IL- 10 receptor, and washed.
• the next step involves detecting bound IL- 10 receptor.
• Rational drug design may also be based upon structural studies of the molecular shapes of the receptor and other effectors or ligands. Effectors may be other proteins which mediate other functions in response to ligand binding, or other proteins which normally interact with the receptor.
• One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or NMR
• Purified receptor can be coated directly onto plates for use in the aforementioned drug screening techniques. However, non-neutralizing antibodies to these receptors can be used as capture antibodies to immobilize the respective receptor on the solid phase.
• IL- 10-like peptides may result from the inhibition of binding of the ligand to the receptor, likely through competitive inhibition.
• in vitro assays of the present invention will often use isolated membranes from cells expressing a recombinant receptor, soluble fragments comprising the ligand binding segments of these receptors, or fragments attached to solid phase substrates. These assays will also allow for the diagnostic determination of the effects of either binding segment mutations and modifications, or ligand mutations and modifications, e.g., ligand analogues .
• This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing antibodies to the receptor or receptor fragments compete with a test compound for binding to the receptor.
• the antibodies can be used to detect the presence of any polypeptide which shares one or more binding sites of the receptor and can also be used to occupy binding sites on the receptor that might otherwise be occupied by IL- 10.
• neutralizing antibodies against the receptor and soluble fragments of the receptor which contain the ligand binding site can be used to inhibit IL- 10 receptor function in, e.g.,
• macrophages B cells, T cells, or related cell types.
• kits and methods for detecting the presence of the IL-10 receptor typically the kit will have a compartment containing either a defined receptor peptide or gene segment or a reagent which recognizes one or the other.
• a kit for determining the binding affinity of a test compound to IL- 10 receptor would typically comprise a test compound; a labeled compound, for example a ligand or antibody having known binding affinity for IL-10 receptor; a source of IL- 10 receptor (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing IL-10 receptor.
• a labeled compound for example a ligand or antibody having known binding affinity for IL-10 receptor
• a source of IL- 10 receptor naturally occurring or recombinant
• a means for separating bound from free labeled compound such as a solid phase for immobilizing IL-10 receptor.
• a preferred kit for determining the concentration of, for example, IL-10 receptor in a sample would typically comprise a labeled compound, e.g., ligand or antibody, having known binding affinity for the receptor, a source of IL-10 receptor (naturally occurring or recombinant) and a means for separating the bound from free labeled compound, for example a solid phase for
• Antibodies including antigen binding fragments, specific for the receptor or receptor fragments are useful in diagnostic
• diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the IL-10 receptor in serum, or the like. Diagnostic assays may be
• RIA radioimmunoassay
• ELISA enzyme-linked immunosorbent assay
• EIA enzyme-multiplied immunoassay technique
• SFIA substrate- labeled fluorescent immunoassay
• Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against a receptor, as such may be diagnostic of various abnormal states. For example, over- or inappropriate production of IL-10 receptor may result in various immunological reactions which may be diagnostic of abnormal receptor expression, particularly in proliferative cell conditions such as cancer.
• the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay.
• the protocol, and the label either labeled or unlabeled antibody, or labeled receptor is provided. This is usually in conjunction with other additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like.
• the kit will also contain instructions for proper use and disposal of the contents after use.
• the kit has compartments for each useful reagent.
• the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium having appropriate concentrations for performing the assay.
• diagnostic assays may be used without modification or may be modified in a variety of ways. For example, they may be labeled as described above.
• the receptor can be immobilized on various matrices followed by washing. Suitable matrices include plastic such as an ELISA plate, filters, and beads. Methods of immobilizing the receptor to a matrix include, without limitation, direct adhesion to plastic, use of a capture antibody, chemical coupling, and biotin-avidin.
• the last step in this approach involves the precipitation of receptor/ligand complex by any of several methods including those utilizing, e.g., an organic solvent such as polyethylene glycol or a salt such as
• ammonium sulfate ammonium sulfate.
• suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described by Rattle et al. [Clin. Chem. 30: 1457 ( 1984)], and double antibody magnetic particle separation described in U.S. Patent No. 4,659,678.
• Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of a receptor for IL- 10. These sequences can be used as probes for detecting abnormal levels of the receptor in defined cells of patients suspected of having, e.g., an autoimmune condition, inability to properly respond to infections or inflammation, or a proliferative cell condition like cancer.
• oligonucleotide or polynucleotide sequences taken from the sequence of a receptor for IL- 10. These sequences can be used as probes for detecting abnormal levels of the receptor in defined cells of patients suspected of having, e.g., an autoimmune condition, inability to properly respond to infections or inflammation, or a proliferative cell condition like cancer.
• nucleotide sequences the labeling of the sequences, and the
• an oligonucleotide probe should have at least about 14 nucleotides, usually at least about 18 nucleotides, and the polynucleotide probes may be up to several kilobases.
• Various labels may be employed, most commonly radionuclides, particularly 32p
• other techniques may also be employed, such as using photoreactive or biotin modified nucleotides for introduction into a polynucleotide.
• the biotin then serves as the site for binding to avidin or antibodies, which may be labeled with a wide variety of labels, such as radionuclides, fluorescers, enzymes, or the like.
• antibodies may be employed which can recognize specific duplexes, including DNA duplexes, RNA duplexes, DNA-RNA hybrid duplexes, or DNA-protein complexes.
• probes to the novel anti-sense RNA may be carried out in any conventional techniques such as nucleic acid hybridization, plus and minus screening, recombinational probing, hybrid released translation (HRT), and hybrid arrested translation (HART). This also includes amplification techniques such as polymerase chain reaction (PCR).
• PCR polymerase chain reaction
• kits may test for combinations of markers. See, e.g., Viallet et al., Progress in Growth Factor Res. 7 : 89 ( 1 989) .
• the IL- 10 receptor naturally occurring or recombinant
• fragments thereof and antibodies thereto should be useful in the treatment of various conditions, e.g., autoimmune conditions, septic and toxic shock conditions, and infectious
• IL-10 receptor likely plays a role in many basic regulatory processes in immune function. Agonists and antagonists of the cytokine will be developed using the present invention. See also, e.g., Harada et al., J. Biol. Chem. 267:22752
• Recombinant IL- 10 receptor including soluble fragments thereof, or IL-10 receptor antibodies can be purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active ingredients, e.g., in
• Drug screening using the IL-10 receptor or fragments thereof can be performed to identify compounds having binding affinity to the IL-10 receptor. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of IL- 10. Likewise, a compound having intrinsic stimulating activity can activate the receptor and is thus an agonist in that it simulates the activity of IL-10. This invention further contemplates the therapeutic use of antibodies to the IL-10 receptor as antagonists.
• treatment dosages should be titrated to optimize safety and efficacy.
• dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents.
• Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage.
• Various considerations are described, e.g.. in Gilman et al. (eds). Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., 1990, Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed., 1990, Mack Publishing Co., Easton, Penn.
• Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Because of the high affinity binding between IL-10 and its receptors, low dosages of these reagents would be initially expected to be effective. Thus, dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 ⁇ M concentrations, usually less than about
• nM 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 100 fM (femtomolar), with an appropriate carrier.
• Slow release formulations, or slow release apparatus will often be utilized for continuous administration.
• the intracellular segments of the receptors, both the IL-10 receptor and related receptors will find additional uses as described in detail below.
• the IL- 10 receptor, fragments thereof, and antibodies to the receptor or its fragments, antagonists, and agonists may be
• Therapeutic 'formulations may be administered in any conventional dosage formulation. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical composition.
• compositions comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof.
• Each carrier must be both pharmaceutical ly and physiologically acceptable in the sense of being compatible with the other
• Formulations include those suitable for oral, rectal, nasal, or parenteral (including
• the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Avis et al. (eds.), Pharmaceutical Dosage Forms: Parenteral Medications, 1993, Dekker, New York;
• the materials of this invention can also be delivered by standard gene therapy techniques, including, e.g., direct DNA
• IL-10 exhibits different specific activities (units per mg of protein) in different biological assays.
• the specfic activity of IL- 10 in cytokine synthesis inhibitory factor assays, where IL-10 acts on macrophages is higher than that observed in costimulation of mouse thymocyte or mouse mast cell proliferation.
• the human and mouse IL-10 receptors provided herein bind IL-10, although the ability of each component by itself to bind vIL- 10 has not yet been demonstrated.
• the apparent Kd of the recombinant IL-10 receptor (100-400 pM) is considerably higher than the EC 50 of IL- 10 on macrophages and monocytes (5-20 pM).
• an accessory molecule might be required for signal transduction upon IL-10 binding .
• Various approaches can be used to screen for such accessory components. These approaches include both physical affinity methods and activity screening. Similar affinity methods as used herein with human IL-10 can be used with vIL- 10. Because vIL-10 is biologically active but has not been shown to bind to the subunits, some modified form of the receptor may exist. A FLAG-vIL-10 fusion construct should be useful in selective purification of cells containing such a receptor form.
• transfect libraries made from appropriate cells e.g., cells capable of responding to vIL-10, to screen transfected cells which otherwise are non-responsive to v-IL-10; or fail to bind to vIL-10 (or the FLAG-vIL- 10 fusion).
• appropriate cells e.g., cells capable of responding to vIL-10
• Such a library of transfected cells could be screened using a FLAG-vIL-10 marker at a
• a FLAG-vIL- 10 fusion construct can be used for panning or FACS separation, e.g., as described below.
• IL-10 component already isolated, e.g., to isolate accessory components which modify the binding properties. Components which increase ligand binding affinity upon association are particularly desired.
• cDNA clones isolated in this manner are characterized, e.g., by sequencing, and compared structurally to other subunits or accessory proteins identified in other receptors.
• iodinated human IL-10 hIL-10
• MC/9 proliferation assays showed that this labeled protein retains greater than 50% biological activity.
• Molecular weight sizing of the purified, iodinated protein indicated that the protein exists
• active hIL- 10 is a non-covalently linked di mer.
• murine mast cell line MC/9 and human B lymphoma line JY have the highest number of accessible, e.g., unoccupied, receptors per cell.
• Human B cell lines Ramos and BH5, as well as erythroleukemia line TF- 1 bind at a reduced level relative to MC/9 and JY, followed by human T cell and macrophage lines. These cell lines were chosen based on the reported
• TF- 1 cell line originally derived from an erythroleukemic patient, is dependent on IL-3, erythropoietin, or
• GM-CSF for long term growth.
• the cell line is also responsive to IL-4, IL-5 and IL-6 in proliferation assays.
• IL-4, IL-5 and IL-6 in proliferation assays.
• Kd values obtained from Scatchard analysis indicate that hIL-10 binds with relatively high affinity to its receptor on both mouse and human cells, and that there are between 100 and 300 unoccupied receptors per cell.
• Competition binding assays with human and murine IL-10 on the mouse mast cell line MC/9 and the human cell line JY demonstrated that while the mouse ligand is able to compete with binding of iodinated hIL- 10 to the mouse cell line, it cannot do so with the human cell line.
• One explanation is that under the binding conditions employed, hIL-10 can recognize and bind to both the mouse and the human receptor, while the mouse IL-10 can only recognize the mouse receptor. Supporting this notion of species specificity of the mouse ligand in binding site-recognition is the absence of any significant biological cross-reactivity of murine IL-10 on human cells.
• Example 1 General Methods
• MC/9 cells (ATCC# CRL 1649) were routinely grown in
• Dulbecco's modified essential medium with 10% fetal bovine serum (FBS) containing 3-5% mitogen-stimulated spleen-conditioned media, 100 U/ml mIL-4, 10 U/ml Penicillin/ Streptomycin,
• TF- 1 cells [Kitamura et al. , J. Cell.
• Physiol. 140:323 ( 1989)] were grown in RPMI 1640 with 10% FBS and 1 ⁇ g/liter mouse GM-CSF.
• JY cells (provided by J. de Vries, DNAX, Palo Alto, CA) were grown in DMEM with 10% FBS, 6 mM glutamine, and antibiotics.
• Other cell lines [Ramos (ATCC# CRL1596), WEHI 265.1 (TIB204), U937 (CRL1593), HL-60 (CCL240), JD (CRL8163), Jijoye (CCL87), THP- 1 (TIB202).
• B-JAB (provided by J. Banchereau, Schering-Plough France), and BH-5 (provided by W. Tadmori,
• tissue culture reagents were from GIBCO (Gaithersburg, MD).
• FACS was performed using standard methods on a
• Becton-Dickinson FACStar PLUS See, e.g., Shapiro, Practical Flow Cytometry (2d ed.), 1988. Alan Liss, New York.
• E. coli-derived human GM-CSF. IFN- ⁇ , and mouse IL-10 were obtained from E. coli-derived human GM-CSF. IFN- ⁇ , and mouse IL-10.
• hIL-10 protein was labeled using the Enzymobead radioiodination reagent (Bio-Rad, Richmond, CA), which is an immobilized preparation of lactoperoxidase and glucose oxidase, following the manufacturer's protocols.
• the purified protein was passed through a PD-10 column (Pharmacia LKB Biotechnology,
• Biological activity of hIL-10 was determined using a
• the cells were centrifuged at 200 x g for 10 minutes, resuspended in 100 ⁇ l of binding buffer without labeled hIL- 10, layered over 200 ⁇ l of a 1 : 1 mixture of dibutyl- and dioctyl-phthalate oils in elongated microcentrifuge tubes, centrifuged at 400 x g for 5 minutes at 4oC , and quick-frozen in liquid nitrogen.
• the cell pellets were then cut and counted in a Clinigamma 1272 counter (Pharmacia LKB). Nonspecific binding was determined by performing the binding in the presence of 500 to 1000-fold molar excess unlabeled hIL-10.
• Cytokine specificity was determined under similar conditions but with the addition of 500-fold molar excess of the cytokines indicated.
• binding medium consisting of PBS, 0.1 % NaN 3 , 10% bovine serum albumin, and 200 pM 1 25 I-hIL- 10 with or without 200 nM unlabeled hIL- 10.
• the cells were washed twice with PBS and then resuspended in 1 ml of PBS.
• the supernatants were harvested and incubated overnight at 4°C with rabbit anti-hIL- 10 polyclonal antiserum which had been prepared by standard methods and presorbed to protein G resin (Pierce Chemical Co.). Each sample contained 20 ⁇ l of the resin.
• a set of prestained molecular weight markers (Life Technologies, Inc.) was run in parallel to determine the size of the cross-linked complexes. After electrophoresis, the gel was dried and exposed to a Kodak XAR film for 48 hours at -80°C with two intensifying screens.
• plasmid DNA Five micrograms of plasmid DNA were mixed with 5 x 10 6 COS 7 cells in 250 ⁇ l of DMEM with 10% FBS and antibiotics in an electroporation cuvette ( Bio-Rad, Richmond, CA).
• the cel ls were electroporated with a Bio-Rad Gene Pulser using 0.20 kV, with the capacitance set at 960 ⁇ F and the resistance at 200 ohms. After 10 minutes at room temperature, the cel ls were transferred to 10 cm dishes with 10 ml of complete medium and allowed to attach.
• the FLAG sequence is recognized by commercially available antibodies
• Example 3 Preparation of cDNA Libraries cDNA libraries were constructed using standard techniques from cell lines which are sensitive to IL- 10. See Superscript Plasmid System for cDNA Systems and Plasmid Cloning, Life Technologies, BRL, Gaithersburg, MD. The BJAB B human cell line was used, as were the mouse MC/9 mast cell and J774 macrophage cell lines.
• Cells transfected with the cDNA libraries were subjected to FACS sorting using biotinylated fluorescent FLAG antibodies as markers. After exposing transformed cel ls to the antibodies, phycoerythrin-streptavidin (PE-streptavidin ) was added. The marked cells were then analyzed by FACS to collect the 3-5% of cells expressing the greatest amount of IL- 10 binding. Selected cells were used to make cDNA libraries, and the cells were subjected to three cycles of enrichment. It was thereby found that IL- 10 can compete with the FLAG-IL- 10 binding.
• PE-streptavidin phycoerythrin-streptavidin
• the isolated inserts from both the human and mouse cDNA sources were further characterized by sequencing by standard method s .
• CHO-derived hIL- 10 was iodinated to high specific activity (100 to 200 ⁇ Ci/ ⁇ g protein ) using the lactoperoxidase method.
• Initial attempts to label CHO-derived hIL-10 with the IODO-GEN reagent (Pierce, Rockford. IL) resulted in protein of insufficient specific activity to be used in receptor characterization.
• the lactoperoxidase method yielded iodinated hIL- 10 with a specific activity approximately five-fold higher than that obtained with IODO-GEN.
• the labeled IL- 10 thus retained 64% of the biological activity.
• the labeled protein mixture when passed through a Sephadex G-75 gel-filtration column, was resolved into three distinct species. This fractionation was found to be necessary to reduce background binding to target cells. The largest species was a high molecular weight form which elutes wi th the excluded volume. The smallest species eluted between the lowest molecular weight standard ( 13.7 kDa) and the dye marker Bromophenol Blue.
• MC/9 cells respond to hIL- 10 by proliferation, so they were first used to determine the binding specificity of hIL- 10.
• the 37 kDa species, but not the other two was able to bind to a high degree; moreover, a 500-fold molar excess of unlabeled IL- 10 protein could block greater than 90% of the labeled I L- 10 binding.
• hIL- 10 binding to its receptor
• other cytokines as well as monoclonal antibodies to hIL- 10 were tested for their ability to inhibit the binding of iodinated hIL-10 to its cell surface receptor. It was found that excess hIL- 10 was capable of competing with labeled hIL-10 in binding to TF- 1 cells. In contrast, hIL-5 , hIL-4, IFN- ⁇ , GM-CSF, and hIL-6 were ineffective in competi ti on .
• Example 10 Species Specificity of Human and Mouse IL-10
• mouse and human IL- 1 0 To examine the species-specificity of receptor binding, the ability of mouse and human IL- 1 0 to compete with labeled human IL- 10 for binding to mouse and human cel l lines w as examined.
• E. coli-derived murine IL- 10 was 60-70% of human IL- 10, as determined by the MC/9 biological assay, the concentrations of human and murine IL- 10 in the competition experiments were adjusted accordingly. Both mouse and human IL-10 were able to block the binding of labeled hIL-10 to the mouse MC/9 line. In contrast, human IL- 10, but not mouse
• IL-10 was able to successfully compete with the binding of labeled hIL-10 to the human B lymphoma line JY.
• Example 1 1 : Multiple Complexes Produced after Chemical
• hIL- 10 receptor binding complexes 1 25 I-hIL- 10 was bound to JY and MC/9 (ATCC CRL 1649) cells, and the cells were treated with EDC as described above. Because the number of hIL- 10 receptors in both cell lines was low, the cell lysates were immunoprecipitated after cross-linking with
• anti-hIL- 10 polyclonal antiserum to enrich the binding complexes.
• both the JY and MC/9 cells yielded hIL- 10-specific binding complexes.
• a major form of binding complex having an estimated molecular weight of about 97 kDa was produced from both cell lines.
• COS7 cells were transfected with the human or mouse cDNA clones, allow ed to express the vector for 72 hours, and tested for binding to radioiodinated human IL- 10. Unlike the vector alone, the cloned receptor cDNA was able to confer specific binding ability for human IL-10 on COS cells. Both the human and mouse clones were able to bind human IL- 10.
• the fusion derivative used to illustrate this invention below is a protein containing the human IL- 10 receptor extracellular domain, the human IL-4 intracellular domain, and either the human IL- 10 or human IL-4 transmembrane domain.
• Such constructs are useful, e.g.. for elucidation of the mechanism of signal transduction by the relevant cytokines.
• the resulting plasmid was designated pSR. Sport.
• BamHl -Pstl fragment was synthesized by PCR using primers designated C3632CC (SEQ ID NO: 5 ) and C3633CC (SEQ I D NO: 6). and plasmid pMEl SS-hIL-4R (ATCC 68263) as the template. An original Sau3 ⁇ site was thereby converted into a B am Hl site by a silent mutation, to facilitate cloning. This fragment was restricted by
• Plasmid pME18S-hIL-4R was then treated with Pstl to release a 900 bp Pstl-Pstl fragment, which was inserted at the Pstl site of plasmid pUC19 that had been modified as described above.
• the resulting construct containing the complete human 1L-4 IC was verified by DNA sequencing.
• the hIL-4 IC was thus reconstructed as a BamHl------Pstl------Pstl insert in pUC19.
• Construction of the EC was also accomplished by ligation of two restriction fragments.
• a Kpnl site was created by a silent mutation at base 346 (the third base of the codon for glycine 95) of the hIL-10 receptor subunit (SEQ ID NO: 1), to facilitate cloning.
• the 5' and 3' end fragments were individually synthesized by PCR and cloned into pUC19 as an EcoRl/Sall--Kpnl fragment and a Kpnl---
• a BstEII site was created by a silent mutation of base
• DNA encoding the hIL-4R TM was synthesized as an
• the hIL-4R IC was excised from the vector described above as a -S ⁇ mHI -H indIII fragment and inserted into the pUC19 vector already containing the hIL- 10R EC.
• a synthetic TM from hIL-4R was then inserted into the pUC19 vector as a BstE II-B am H l fragment, to generate a plasmid containing ful l-length chimeric receptor DNA.
• the EcoRl/Sall-Kpnl-BstEII-Stop/EcoRl/Bam Hl fragment described above was excised from the vector as an Eco R I -----EcoR l fragment and cloned into pDSRG for direct transfection, or excised as an EcoRI-end-filled and Sail fragment and cloned into Sall/SnaB l restricted pSR. Sport for co-transfection with pDSRG.
• a human IL-10 affinity column was constructed by
• cross-linking hIL- 10 prepared by standard methods (See U.S.
• Patent No. 5.231 ,012 to Mosmann el al. to N-hydroxysuccinimide ester-activated agarose gel beads.
• Conditioned medium from transfected cells producing the soluble receptor was applied to the column, and the column was washed with PBS containing 0.5 M NaCl and 0.1 % octylglucoside.
• the column was then loaded with 2 M MgCl 2 (pH 7.5) to release bound soluble hIL- 10 receptor, and the eluted product was analyzed by SDS-PAGE with si lver staining.
• the eluted product was first dialyzed into PBS and then treated with endoglycanase F (N-glycanase) and analyzed, along with the untreated product, by electrophoresis and Western blotting.
• Interleukin-10 (IL-10)
• ATC CCA AAT CAG TCT GAA AGT ACC TGC TAT GAA GTG GCG CTC GTG AGG 250 Ile Pro Asn Gln Ser Glu Ser Thr Cys Tyr Glu Val Ala Leu Leu Arg
• GAG ACC CAA GAC ACC ATC CAC CCG CTT GAT GAG GAG GCC TTT TTG AAG 970 Glu Thr Gln Asp Thr Ile His Pro Leu Asp Glu Glu Ala Phe Leu Lys
• AAAGCTCTGT CAATAAGTGA TACATGTTTT TTATTCCAAT AAATTGTCAA GACCACA 3632
• AAC AGT CAG TAC TCC AAC TGG ACC ACC ACT GAG ACT CGC TTC ACA GTG 448 Asn Ser Gln Tyr Ser Asn Trp Thr Tnr Thr Glu Thr Arg Phe Thr Val
• GGC ATC ATC TAT GGG ACA ATC CAT CCC CCC AGG CCC ACG ATA ACC CCT 544 Gly Ile Ile Tyr Gly Thr Ile His Pro Pro Arg Pro Thr Ile Thr Pro 140 145 150 135
• AAA CAG GAA ACC TTC ACC CTC ACG GTC CCC ATA GGG GTG AGA AAG TTT 688 Lys Gln Glu Thr Phe Thr Leu Thr Val Pro Ile Gly Val Arg Lys Phe
• CAG AAA CAG ACC AGA TGG AAG GCA GAG GCA GCA GCA GGC CCA GCA GAA TGC 1456 Gln Lys Gln Tnr Arg Trp Lys Ala Glu Ala Ala Gly Pro Ala Glu Cys
• CTCCCCTCCC TGTACCTGGG AGGCTCAGGA GTCAAAGAAA TATGTGGGTC CTTTTCTGCA 1904

Priority Applications (8)

Applications Claiming Priority (6)

Publications (1)

Family

ID=27359359

Family Applications (1)

Country Status (15)

Cited By (10)

Families Citing this family (23)

• 1993
  • 1993-08-23 US US08/110,683 patent/US5789192A/en not_active Expired - Lifetime
  • 1993-12-07 ES ES94903375T patent/ES2129622T3/es not_active Expired - Lifetime
  • 1993-12-07 AU AU57340/94A patent/AU5734094A/en not_active Abandoned
  • 1993-12-07 DE DE69323765T patent/DE69323765T2/de not_active Expired - Lifetime
  • 1993-12-07 WO PCT/US1993/011638 patent/WO1994013801A1/en active IP Right Grant
  • 1993-12-07 DK DK94903375T patent/DK0673420T3/da active
  • 1993-12-07 JP JP06514231A patent/JP3135576B2/ja not_active Expired - Fee Related
  • 1993-12-07 CA CA002151141A patent/CA2151141C/en not_active Expired - Lifetime
  • 1993-12-07 AT AT94903375T patent/ATE177147T1/de not_active IP Right Cessation
  • 1993-12-07 EP EP94903375A patent/EP0673420B1/en not_active Expired - Lifetime
  • 1993-12-09 MY MYPI93002646A patent/MY109045A/en unknown
  • 1993-12-09 IL IL10795193A patent/IL107951A/xx not_active IP Right Cessation
  • 1993-12-10 CN CN93121682A patent/CN1052510C/zh not_active Expired - Fee Related
• 1995
  • 1995-06-07 US US08/472,097 patent/US5985828A/en not_active Expired - Fee Related
  • 1995-06-07 US US08/477,166 patent/US5863796A/en not_active Expired - Lifetime
• 1998
  • 1998-07-29 HK HK98109509A patent/HK1008830A1/xx not_active IP Right Cessation
• 1999
  • 1999-04-23 GR GR990401115T patent/GR3030038T3/el unknown
  • 1999-11-15 US US09/439,672 patent/US6423500B1/en not_active Expired - Fee Related

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events